Jove
Visualize
Contact Us

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting GluN2B-containing NMDA receptors to interact with stress pathways and Ca<sup>2+</sup>-regulated K<sup>+</sup> channels in murine islets of Langerhans.

European journal of pharmacology·2025
Same author

Nitro-oleic acid enhances mitochondrial metabolism and ameliorates heart failure with preserved ejection fraction in mice.

Nature communications·2025
Same author

Resolving Spatiotemporal Electrical Signaling Within the Islet via CMOS Microelectrode Arrays.

Diabetes·2024
Same author

A novel fluorescent labeling compound for GluN2A containing <i>N</i>-methyl-d-aspartate receptors identified by autodisplay-based screening.

Journal of pharmaceutical analysis·2024
Same author

Inhibition of mTOR prevents glucotoxicity-mediated increase of SA-beta-gal, p16<sup>INK4a</sup>, and insulin hypersecretion, without restoring electrical features of mouse pancreatic islets.

Biogerontology·2024
Same author

Targeting K<sub>Ca</sub>3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells.

Cell death discovery·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 18, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Glitazones exert multiple effects on β-cell stimulus-secretion coupling.

Martina Düfer1, Katja Noack, Armin Edalat

  • 1Institute of Pharmacy, Department of Pharmacology, University of Tübingen, Auf der Morgenstelle 8, D-72076 Tübingen, Germany.

Molecular Pharmacology
|October 2, 2012
PubMed
Summary

Glitazones impact pancreatic beta-cell function unpredictably, affecting insulin secretion through complex mechanisms. Pioglitazone appears to have negligible effects on beta-cells in vivo.

More Related Videos

A Model of Chronic Nutrient Infusion in the Rat
08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Related Experiment Videos

Last Updated: May 18, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

A Model of Chronic Nutrient Infusion in the Rat
08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Area of Science:

  • Endocrinology
  • Pharmacology
  • Cell Biology

Background:

  • Glitazones are used for type 2 diabetes, potentially improving insulin secretion and peripheral insulin sensitivity.
  • The precise effects of glitazones on pancreatic beta-cell stimulus-secretion coupling (SSC) remain unclear.

Purpose of the Study:

  • To investigate the influence of troglitazone and pioglitazone on various parameters of beta-cell SSC.
  • To elucidate the mechanisms underlying glitazone-induced changes in insulin secretion.

Main Methods:

  • Radioimmunoassay for insulin secretion.
  • Patch-clamp technique for ion currents.
  • Fluorescence measurements for cytosolic Ca(2+) and mitochondrial membrane potential (ΔΨ).

Main Results:

  • Troglitazone exhibited variable effects on insulin secretion, influenced by glucose concentration.
  • Troglitazone altered mitochondrial membrane potential, ATP production, and ion channel activity (K(ATP), voltage-dependent Ca(2+) and K(+) channels).
  • Pioglitazone showed less impact on beta-cell SSC compared to troglitazone; effects of both were reduced by bovine serum albumin.

Conclusions:

  • Glitazones exert multiple, potentially uncontrollable actions on beta-cell SSC, which may be considered side effects.
  • The net effect of glitazones on insulin secretion is multifactorial, depending on drug concentration, glucose levels, and protein binding.
  • Pioglitazone's effects on beta-cells are likely minimal under in vivo conditions, unlike troglitazone.